rituximab,polatuzumab vedotin
roche
['dlbcl']
#ash22: results from a clinical trial suggest that testing levels of circulating tumor dna (ctdna) in previously untreated dlbcl patients after one to two cycles of induction therapy could help predict disease outcomes as presented by alex herrera, m.d. at ash. 
City of Hope is a National Cancer Institute-designated comprehensive cancer center for cancer, diabetes and other life-threatening diseases.